Risk Factors for Prostate Cancer: An Umbrella Review of Prospective Observational Studies and Mendelian Randomization Analyses

Finasteride may affect male offspring's fertility and hormonal balance, with debates on whether to discontinue use before conception. Some users report no issues, while others highlight the high doses used in rat studies.

Pattern hair loss before age 35 may be linked to higher risks of prostate cancer, cardiovascular diseases, and metabolic syndrome later in life. Finasteride is discussed as a treatment that may lower PSA levels and potentially prevent prostate issues.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

Dutasteride treatment may decrease sperm concentration, but levels remain above WHO recommendations and recover after discontinuation. The study has limitations, including small sample size and lack of pre-treatment sperm data, and does not assess other fertility factors.

Concerns about the long-term effects of dutasteride and finasteride on fertility, with discussions on cycling these medications to mitigate risks. The conversation highlights skepticism about study methodologies and the importance of weighing treatment risks against potential fertility issues.